Last reviewed · How we verify

NCT04410640

Surgical Planning With Patient-specific Pancreaticobiliary Disease With 3D Models

Completed Last updated 1 June 2020
What this trial tests

trial testing survey in Surgical Injury in 19 participants. Completed in 10 January 2020.

Timeline
10 July 2019
Primary endpoint
10 November 2019
10 January 2020

Quick facts

Lead sponsorEge University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment19
Start date10 July 2019
Primary completion10 November 2019
Estimated completion10 January 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ege University

Who can join

Adults 24 to 30, any sex, with Surgical Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Three-dimensional (3D) printing has been increasingly used in medical applications with the creation of accurate patient-specific 3D printed models in medical imaging data. However, research on 3D printing in pancreaticobiliary disease is limited with lack of studies on validation of model accuracy. Methods: This is a where general surgery residents, are introduced to 5 distinct hepatopancreatobiliary disease scenarios to generate a perception and required to compare their perception level of these cases with computed tomography (CT), 3D images and 1:1 solid models that the pathology, diverse diagnosis and presurgery diagnosis stages can be investigated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of survey

Trials testing the same drug.

Other Ege University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04410640.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing